Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
ADAdial Pharmaceuticals, Inc. logo

Adial Pharmaceuticals, Inc. (ADIL)

NASDAQ Capital Market · Currency in USD
$3.92 ▼ -0.30 (-7.11%)
At close: Oct 23, 4:00 PM ET. Market closed.
$3.92 ▲ +0.00 (+0.00%)
After hours: Oct 23, 4:10 PM ET

Summary

Previous Close
$4.22
Open
$4.17
Day's Range
$3.80 – $4.28
52 Week Range
$1.31 – $9.50
Volume
47,359
Avg. Volume
60,298
Market Cap
$10.29M
Beta (5Y Monthly)
1.50
PE Ratio (TTM)
--
EPS (TTM)
-$12.51
Earnings Date
Nov 18, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$8.50

Profile: Adial Pharmaceuticals, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
5
CEO
Cary John Claiborne
Website
adial.com

Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions.

Earnings

Next report: Wed, Nov 18, 2026
EPS estimate -$0.18
DateEst.Actual
Aug 12, 2026-$1.03-$11.25Miss
May 13, 2026-$2.73-$1.48Beat
Mar 10, 2026-$2.10-$1.81Beat
Nov 13, 2025-$2.25-$2.00Beat
Aug 13, 2025-$5.50-$4.50Beat
May 14, 2025-$12.50-$8.50Beat

Analyst view

Consensus price target
$8.50 ▲ +116.8%
Range $6.00 – $11.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on ADIL and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.